ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · IEX Real-Time Price · USD
16.59
-0.15 (-0.90%)
At close: Apr 24, 2024, 4:00 PM
16.69
+0.10 (0.60%)
After-hours: Apr 24, 2024, 6:40 PM EDT
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for ACAD stock have an average target of 30.9, with a low estimate of 19 and a high estimate of 42. The average target predicts an increase of 86.26% from the current stock price of 16.59.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACAD stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 7 | 6 | 6 |
| Buy | 5 | 6 | 7 | 7 | 7 | 7 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 18 | 19 | 20 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $37 | Buy | Reiterates | $37 | +123.03% | Apr 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +92.89% | Apr 9, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $29 → $25 | Buy | Maintains | $29 → $25 | +50.69% | Mar 25, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $40 → $30 | Buy | Maintains | $40 → $30 | +80.83% | Mar 13, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $38 → $30 | Strong Buy | Maintains | $38 → $30 | +81.98% | Mar 12, 2024 |
Financial Forecast
Revenue This Year
986.42M
from 726.44M
Increased by 35.79%
Revenue Next Year
1.12B
from 986.42M
Increased by 13.14%
EPS This Year
0.68
from -0.37
EPS Next Year
1.32
from 0.68
Increased by 94.22%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.0B | 1.2B | 1.6B | 3.0B | 2.5B |
| Avg | 986.4M | 1.1B | 1.3B | 1.8B | 1.8B |
| Low | 920.2M | 973.3M | 1.0B | 1.2B | 1.3B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 43.0% | 24.8% | 47.4% | 132.7% | 40.3% |
| Avg | 35.8% | 13.1% | 14.0% | 39.5% | 0.6% |
| Low | 26.7% | -1.3% | -7.4% | -3.6% | -25.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.30 | 2.27 | 3.47 | 9.56 | 3.77 |
| Avg | 0.68 | 1.32 | 1.88 | 4.03 | 2.63 |
| Low | 0.29 | 0.77 | 0.84 | 1.56 | 1.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 233.6% | 162.7% | 409.5% | -6.5% |
| Avg | - | 94.2% | 42.2% | 115.0% | -34.7% |
| Low | - | 14.0% | -36.1% | -16.9% | -62.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.